RxDoctor Payments Data

Jorge Montero

Family · Buford, GANPI 1457022147

Payments from drug & device makers

$2,900in general payments, 2019–2025

Across 41 payments — averaging $70.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$600
  • Amgen$332
  • Novo Nordisk$277
  • Astellas Pharma US Inc$275
  • Bayer$241
  • AbbVie$224
  • plus $950 from 8 others

What the payments were for

  • Food & beverage$2,32380%
  • Education$1565%
  • Other$42115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,900 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$23,097
Medicare patients
102
Services billed
2,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide31$53,846
JardianceEmpagliflozin26$45,262
OzempicSemaglutide32$43,943
LinzessLinaclotide19$23,586
EliquisApixaban11$19,072
MounjaroTirzepatide12$16,958
FarxigaDapagliflozin Propanediol12$13,604
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,252
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,565
Rosuvastatin Calcium108$1,581
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid17$1,553
Gabapentin81$1,542
Diclofenac Sodium91$1,154
Atorvastatin Calcium112$968
Levothyroxine Sodium111$931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$36$70,80443 claims
Novo NordiskOzempic$277$43,94332 claims
AbbVieLinzess$224$23,58619 claims
PfizerEliquis$169$19,07211 claims
AstraZenecaFarxiga$600$13,60412 claims
GSKTrelegy Ellipta$143$8,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →